Greenwich Lifesciences

GLSI · NASDAQ

$16.24+$1.03 (+6.77%)TodayMarket closed · Oct 20, 7:32 PM ET

Prev close $15.21

GLSI analyst rating

BuyConsensus of 1 analyst over the last 12 months. 100% rate it a buy.

Strong buy0
Buy1
Hold0
Underperform0
Sell0

12-month price target · 3 analysts

Average $70.38 (+333.4% upside)

Low: $69.69
Now: $16.24
High: $72.45

Upgrades and downgrades

The latest rating actions, newest first

GLSI analyst upgrades, downgrades and rating actions
Firm	Date	Action	Rating	Price target	Hit rate
HC Wainwright & Co.	Jul 21, 2026	Maintains	Buy	$50.00 → $69.00	40%
HC Wainwright & Co.	Dec 30, 2025	Maintains	Buy	$39.00 → $50.00	40%

The case for and against

Updated Oct 7, 2025

Bull case

Greenwich LifeSciences Inc. has reported promising immune response data from its Phase III FLAMINGO-01 trial of GLSI-100, indicating a positive trend in immune responses among patients throughout the vaccination period. The encouraging preliminary results suggest the potential for substantial patient eligibility, potentially doubling the target population to around 88,000 new patients annually in the U.S. Additionally, the ongoing expansion of Flamingo-01 into Europe, with plans for up to 150 global sites, could enhance the company’s market reach and overall growth prospects.

Bear case

Greenwich LifeSciences Inc. reported a net loss of $15.8 million, amounting to $1.21 per share, indicating substantial financial challenges as the company advances its Phase III clinical trial, Flamingo-01. The outlook is further complicated by significant risks including the potential failure of the GP2 immunotherapy in clinical trials, difficulties in obtaining regulatory approval, and the possibility of unmet commercial success due to market size, penetration rates, and competition. Additionally, there is a concern regarding dilution risk, which could exacerbate the financial instability and negatively impact shareholder value.

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.